Noninvasive early indicators of treatment response are crucial to the successful delivery of precision medicine in children with cancer. Neuroblastoma is a common solid tumor of young children that arises from anomalies in neural crest development. Therapeutic approaches aiming to destabilize MYCN protein, such as small-molecule inhibitors of Aurora A and mTOR, are currently being evaluated in early phase clinical trials in children with high-risk MYCN-driven disease, with limited ability to evaluate conventional pharmacodynamic biomarkers of response. T-1 mapping is an MRI scan that measures the proton spin-lattice relaxation time T-1. Using a multiparametric MRI-pathologic cross-correlative approach and computational pathology methodologies including a machine learning-based algorithm for the automatic detection and classification of neuroblasts, we show here that T-1 mapping is sensitive to the rich histopathologic heterogeneity of neuroblastoma in the Th-MYCN transgenic model. Regions with high native T-1 corresponded to regions dense in proliferative undifferentiated neuroblasts, whereas regions characterized by low T-1 were rich in apoptotic or differentiating neuroblasts. Reductions in tumor-native T-1 represented a sensitive biomarker of response to treatment-induced apoptosis with two MYCN-targeted small-molecule inhibitors, Aurora A kinase inhibitor alisertib (MLN8237) and mTOR inhibitor vistusertib (AZD2014). Overall, we demonstrate the potential of T-1 mapping, a scan readily available on most clinical MRI scanners, to assess response to therapy and guide clinical trials for children with neuroblastoma. The study reinforces the potential role of MRI-based functional imaging in delivering precision medicine to children with neuroblastoma.Significance: This study shows that MRI-based functional imaging can detect apoptotic responses to MYCN-targeted small-molecule inhibitors in a genetically engineered murine model of MYCN-driven neuroblastoma.

Zormpas Petridis, K., Poon, E., Clarke, M., Jerome, N., Boult, J., Blackledge, M., Carceller, F., Koers, A., Barone, G., Pearson, A., Moreno, L., Anderson, J., Sebire, N., Mchugh, K., Koh, D., Chesler, L., Yuan, Y., Robinson, S., Jamin, Y., Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma, <<CANCER RESEARCH>>, 2020; 80 (16): 3424-3435. [doi:10.1158/0008-5472.CAN-20-0133] [https://hdl.handle.net/10807/304477]

Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma

Zormpas Petridis, Konstantinos;
2020

Abstract

Noninvasive early indicators of treatment response are crucial to the successful delivery of precision medicine in children with cancer. Neuroblastoma is a common solid tumor of young children that arises from anomalies in neural crest development. Therapeutic approaches aiming to destabilize MYCN protein, such as small-molecule inhibitors of Aurora A and mTOR, are currently being evaluated in early phase clinical trials in children with high-risk MYCN-driven disease, with limited ability to evaluate conventional pharmacodynamic biomarkers of response. T-1 mapping is an MRI scan that measures the proton spin-lattice relaxation time T-1. Using a multiparametric MRI-pathologic cross-correlative approach and computational pathology methodologies including a machine learning-based algorithm for the automatic detection and classification of neuroblasts, we show here that T-1 mapping is sensitive to the rich histopathologic heterogeneity of neuroblastoma in the Th-MYCN transgenic model. Regions with high native T-1 corresponded to regions dense in proliferative undifferentiated neuroblasts, whereas regions characterized by low T-1 were rich in apoptotic or differentiating neuroblasts. Reductions in tumor-native T-1 represented a sensitive biomarker of response to treatment-induced apoptosis with two MYCN-targeted small-molecule inhibitors, Aurora A kinase inhibitor alisertib (MLN8237) and mTOR inhibitor vistusertib (AZD2014). Overall, we demonstrate the potential of T-1 mapping, a scan readily available on most clinical MRI scanners, to assess response to therapy and guide clinical trials for children with neuroblastoma. The study reinforces the potential role of MRI-based functional imaging in delivering precision medicine to children with neuroblastoma.Significance: This study shows that MRI-based functional imaging can detect apoptotic responses to MYCN-targeted small-molecule inhibitors in a genetically engineered murine model of MYCN-driven neuroblastoma.
2020
Inglese
Zormpas Petridis, K., Poon, E., Clarke, M., Jerome, N., Boult, J., Blackledge, M., Carceller, F., Koers, A., Barone, G., Pearson, A., Moreno, L., Anderson, J., Sebire, N., Mchugh, K., Koh, D., Chesler, L., Yuan, Y., Robinson, S., Jamin, Y., Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma, <<CANCER RESEARCH>>, 2020; 80 (16): 3424-3435. [doi:10.1158/0008-5472.CAN-20-0133] [https://hdl.handle.net/10807/304477]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/304477
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact